Atezolizumab |
Locally advanced or metastatic UC as monotherapy Locally advanced or metastatic NSCLC after prior chemotherapy Unresectable locally advanced or metastatic TNBC (in combination with nab-paclitaxel) |
hypothyroidism (very common in combination therapy, common as monotherapy) | hyperthyroidism, diabetes mellitus, adrenal insufficiency | hypophysitis | [ |
Avelumab |
Metastatic MCC RCC (in combination with axitinib) |
hypothyroidism | adrenal insufficiency, hyperthyroidism, thyroiditis, autoimmune thyroiditis, adrenocortical insufficiency acute, autoimmune hypothyroidism, hypopituitarism, type 1 diabetes mellitus | - | [ |
Durvalumab |
Locally advanced, unresectable NSCLC |
hypothyroidism, hyperthyroidism | adrenal insufficiency, type 1 diabetes mellitus | hypophysitis / hypopituitarism, diabetes insipidus | [ |
Ipilimumab |
Advanced melanoma (as monotherapy/in combination with ipilimumab) Adjuvant treatment of melanoma NSCLC as monotherapy RCC relapsed or refractory cHL after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin SCCHN Urothelial Carcinoma |
hypothyroidism, hyperthyroidism | adrenal insufficiency, hypopituitarism, hypophysitis, thyroiditis, diabetes mellitus | diabetic ketoacidosis | [ |
Pemprolizumab |
Advanced melanoma Adjuvant treatment of adults with Stage III melanoma NSCLC cHL Urothelial carcinoma SCCHN |
hypothyroidism, hyperthyroidism | adrenal insufficiency, hypophysitis, thyroiditis | - | [ |
Pemprolizumab |
NSCLC |
hypothyroidism, hyperthyroidism | hypophysitis, thyroiditis, adrenal insufficiency | - | [ |
Pemprolizumab |
Advanced RCC |
hypothyroidism, hyperthyroidism, hypophysitis, thyroiditis, adrenal insufficiency | - | - | [ |